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The discovery of the first curative HCV drug, Sovaldi, revolutionized treatment regimens
for patients of varying genotypes suffering from HCV infection, giving hope to millions
throughout the world infected with the deadly virus. However, the high price of Sovaldi
made it unlikely that many of the patients who are expected to benefit mostfrom the drug's
efficacy would receive treatment. This disparity in obtainingSovaldi, between low-income
and high-income patients, led to an ethical quandary as to how to distribute the drug.
While the public condemned Sovaldi 's manufacturer,GileadSciences,for setting Sovaldi 's
price so high, evidence suggests that Gilead did not act unethically. Rather, the evidence
suggests that the price of Sovaldi can be ethically justified, in part, by its uniquely high
quality, and explained in part by legal constructs in the United States that result in burden
to insurance companies and lead pharmaceuticalcompanies to set high drug prices to
counteractsubstantiallosses during the research and development process.
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The Trump administrationand a number of like-minded states are seeking to impose, for
the first time in the history of the program, work requirements and other, more stringent
"personalresponsibility" requirements on certain Medicaid beneficiaries. This article
uses evidence from the imposition of similar requirements in Temporary Aid for Needy
Families ("TANF'), the cash welfare programfor impoverished Americans, to consider
what may happen if such requirements are imposed in Medicaid. It is clear that work
requirements and, in some cases, time limits were correlated with a sharp and rapid
reduction in TANF rolls. However, it is less clear why that was the case. Substantial
flexibility at state and even local levels in implementing and policing policies, differing
family circumstancesamong TANF recipients,andfluctuations in the economy and in other
federal support programsfor the working poor affected the impact of TANF policies on
program take-up and continuation. They also made it more difficult to disambiguate the
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effects of different policies. One might expect to see similar issues if such changes are also
made to Medicaid.
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Negligence Claims
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Evidence of the breach of duty is the crux of medical malpracticelitigation,and uncertainty
reigns regarding what should be considered the due level of care. According to some
scholars, this uncertainty has fueled the practice of defensive medicine. Consequently,
some proposals to define the medical standardof carepurportto abate defensive medicine.
This article discusses why merely modifying the standard of care would not reduce
defensive medicine. However, since the legal definition of the standard of care may
influence physicians' course of action, this article discusses and proposes in what the
reasonable standardof care employed by the legal system should consist.
In this article,I analyze why "customarypractice" is an inappropriatecriterionon which
to base the legal standardof care, and thereby, to determine whether a physician acted
reasonably, under a substantial and proceduralpoint of view. I explore why the truly
"reasonablephysician" is the one who adopts an evidence-based approachand, thus, why
evidence based medicine ("EBM") should be the golden reasonable standard of care.
Keeping into due account that medical malpractice decision-makers the jurors and the
judge - are not medical experts, I suggest a way to translate the medical lexicon, so as to
be effectively understood by lay people. The article conceptuallyseparates the standardof
care authorized by substantive law from the standard's evidence in court. In this sense,
what is reasonable expresses a different concept from what can be proved as such in a
court of law.
In thisframe, I suggest a wider and influential use in court of ClinicalPractice Guidelines
("CPGs ") as one, despite not the only one, expression of EBM. Because CPGs are not
without certain flaws, I propose a method for scrutinizing guidelines for reliability,
focusing on these tools' underlying knowledge and sources.
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